Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides.
View/ Open
Date
2021-01-11ICR Author
Author
Vitale, I
Yamazaki, T
Wennerberg, E
Sveinbjørnsson, B
Rekdal, Ø
Demaria, S
Galluzzi, L
Type
Journal Article
Metadata
Show full item recordAbstract
Accumulating preclinical and clinical evidence indicates that high degrees of heterogeneity among malignant cells constitute a considerable obstacle to the success of cancer therapy. This calls for the development of approaches that operate - or enable established treatments to operate - despite such intratumoral heterogeneity (ITH). In this context, oncolytic peptides stand out as promising therapeutic tools based on their ability to drive immunogenic cell death associated with robust anticancer immune responses independently of ITH. We review the main molecular and immunological pathways engaged by oncolytic peptides, and discuss potential approaches to combine these agents with modern immunotherapeutics in support of superior tumor-targeting immunity and efficacy in patients with cancer.
Collections
Research team
Radiation-enhanced Immunotherapy
Radiation-enhanced Immunotherapy
Language
eng
Date accepted
2020-12-15
License start date
2021-01-11
Citation
Trends in cancer, 2021
Publisher
CELL PRESS